This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: **Anne DE PAEPE: Pioneering Innovations in Pharmaceutical Compounds**
Introduction
Anne DE PAEPE is a notable inventor based in Basel, Switzerland, recognized for her innovative contributions to the field of pharmaceuticals. With a focus on developing novel compounds, she has made significant strides in the area of pyrido derivatives, marking her as a key player in the research and development landscape.
Latest Patents
Anne holds a patent for her groundbreaking work titled "Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation, and its process of making." This invention is centered around a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one, which is recognized for its potential as a pharmaceutically active compound.
Career Highlights
Throughout her career, Anne has dedicated her efforts to the advancement of pharmaceutical sciences. Her work at Hoffmann-La Roche Inc., a leading global healthcare company, underscores her commitment to research and innovation in creating effective therapeutic solutions. Her expertise and contributions in synthesizing new chemical entities have propelled her into the forefront of drug development.
Collaborations
In her role at Hoffmann-La Roche Inc., Anne has likely engaged in various collaborations with fellow researchers and institutions, fostering advancements in her field. Such partnerships are vital in driving progress and accelerating the development of new treatments that can address unmet medical needs.
Conclusion
Anne DE PAEPE stands out as an accomplished inventor in the pharmaceutical industry, with a patented innovation that has the potential to impact healthcare significantly. Her work exemplifies the importance of innovation and collaboration in the quest for new therapeutic solutions, solidifying her legacy as a leader in pharmaceutical research.
